Insider Selling: Alignment Healthcare (NASDAQ:ALHC) CEO Sells 82,299 Shares of Stock

Alignment Healthcare, Inc. (NASDAQ:ALHC) CEO John Kao sold 82,299 shares of the company’s stock in a transaction that occurred on Monday, April 13th. The stock was sold at an average price of $20.80, for a total value of $1,711,819.20. Following the transaction, the chief executive officer directly owned 1,806,641 shares of the company’s stock, valued at approximately $37,578,132.80. The trade was a 4.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Alignment Healthcare Price Performance

NASDAQ ALHC traded up $0.48 during mid-day trading on Monday, hitting $20.98. The stock had a trading volume of 1,753,989 shares, compared to its average volume of 3,132,918. The firm’s 50 day moving average is $19.29 and its 200 day moving average is $19.04. Alignment Healthcare, Inc. has a twelve month low of $11.63 and a twelve month high of $23.87. The company has a debt-to-equity ratio of 1.80, a current ratio of 1.71 and a quick ratio of 1.71. The stock has a market capitalization of $4.29 billion, a price-to-earnings ratio of -2,095.90, a PEG ratio of 3.00 and a beta of 1.20.

Alignment Healthcare (NASDAQ:ALHC) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.10. Alignment Healthcare had a negative return on equity of 0.49% and a negative net margin of 0.02%.The firm had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. During the same period in the prior year, the company earned ($0.16) EPS. The firm’s revenue was up 44.4% compared to the same quarter last year. Equities research analysts forecast that Alignment Healthcare, Inc. will post -0.69 earnings per share for the current fiscal year.

Institutional Trading of Alignment Healthcare

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Royal Bank of Canada raised its position in shares of Alignment Healthcare by 92.6% during the 1st quarter. Royal Bank of Canada now owns 92,379 shares of the company’s stock valued at $1,720,000 after buying an additional 44,413 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Alignment Healthcare by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 59,557 shares of the company’s stock valued at $1,109,000 after acquiring an additional 2,594 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in Alignment Healthcare by 79.1% in the first quarter. Goldman Sachs Group Inc. now owns 972,715 shares of the company’s stock valued at $18,112,000 after acquiring an additional 429,703 shares during the last quarter. Woodline Partners LP acquired a new position in Alignment Healthcare in the first quarter valued at approximately $2,142,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Alignment Healthcare by 16.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 307,655 shares of the company’s stock valued at $5,729,000 after acquiring an additional 44,452 shares during the last quarter. Institutional investors and hedge funds own 86.19% of the company’s stock.

Wall Street Analyst Weigh In

ALHC has been the subject of several recent research reports. Piper Sandler increased their price objective on Alignment Healthcare from $20.00 to $30.00 and gave the company an “overweight” rating in a research note on Tuesday, January 6th. JPMorgan Chase & Co. increased their price objective on Alignment Healthcare from $23.00 to $26.00 and gave the company an “overweight” rating in a research note on Thursday, February 5th. UBS Group increased their price objective on Alignment Healthcare from $18.00 to $21.00 and gave the company a “neutral” rating in a research note on Wednesday, January 14th. Wall Street Zen downgraded Alignment Healthcare from a “buy” rating to a “hold” rating in a research note on Saturday, March 7th. Finally, TD Cowen upped their target price on Alignment Healthcare from $18.50 to $25.00 and gave the company a “buy” rating in a report on Friday, January 16th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Alignment Healthcare currently has an average rating of “Moderate Buy” and an average target price of $24.75.

About Alignment Healthcare

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.